Factors affecting the performance of different long terminal repeats in the retroviral vector

Biochemical and Biophysical Research Communications

Volumn 343, Issue 4, 2006, Pages 1017-1022

  Kim, Sujeong ^a   Lee, Karim ^b   Kim, Mi Dong ^a   Kang, Seock ^a   Joo, Chang Wan ^a   Kim, Jong Mook ^a   Kim, Seon Hee ^c   Yu, Seung Shin ^a   Kim, Sunyoung ^a,b  

^a ViroMed Co Ltd   (South Korea)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gene expression; LTR; Retroviral vector

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; LUCIFERASE; RETROVIRUS VECTOR; STEM CELL FACTOR;

ARTICLE; CELL TYPE; GENE CASSETTE; GENE EXPRESSION; INTERNAL RIBOSOME ENTRY SITE; LONG TERMINAL REPEAT; MOLONEY LEUKEMIA ONCOVIRUS; MOLONEY MURINE SARCOMA ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SPLEEN FOCUS FORMING VIRUS; STATISTICAL SIGNIFICANCE; TRANSGENE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LEUKEMIA VIRUS, MURINE; LUCIFERASES; MOLONEY MURINE LEUKEMIA VIRUS; RETROVIRIDAE; SARCOMA VIRUSES, MURINE; STEM CELL FACTOR; TERMINAL REPEAT SEQUENCES; TRANSGENES;

MOLONEY MURINE LEUKEMIA VIRUS; MOLONEY MURINE SARCOMA VIRUS; MURINAE; MYELOPROLIFERATIVE SARCOMA VIRUS; SPLEEN FOCUS-FORMING VIRUS;

EID: 33646072451     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.035     Document Type: Article

References (23)

1. Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., Greenblatt J.J., Rosenberg S.A., Klein H., Berger M., Mullen C.A., Ramsey W.J., Muul L., Morgan R.A., and Anderson W.F. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270 (1995) 475-480
2. Hawley R.G., Lieu F.H., Fong A.Z., and Hawley T.S. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1 (1994) 136-138
3. Baum C., Hegewisch-Becker S., Eckert H.G., Stocking C., and Ostertag W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J. Virol. 69 (1995) 7541-7547
4. Robbins P.B., Yu X.J., Skelton D.M., Pepper K.A., Wasserman R.M., Zhu L., and Kohn D.B. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J. Virol. 71 (1997) 9466-9474
5. Hildinger M., Eckert H.G., Schilz A.J., John J., Ostertag W., and Baum C. FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells. Gene Ther. 5 (1998) 1575-1579
6. Challita P.M., Skelton D., el-Khoueiry A., Yu X.J., Weinberg K., and Kohn D.B. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J. Virol. 69 (1995) 748-755
7. Sun W., Graves B.J., and Speck N.A. Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins. J. Virol. 69 (1995) 4941-4949
8. Granger S.W., and Fan H. In vivo footprinting of the enhancer sequences in the upstream long terminal repeat of Moloney murine leukemia virus: differential binding of nuclear factors in different cell types. J. Virol. 72 (1998) 8961-8970
9. Tsukiyama T., Niwa O., and Yokoro K. Mechanism of suppression of the long terminal repeat of Moloney leukemia virus in mouse embryonal carcinoma cells. Mol. Cell. Biol. 9 (1989) 4670-4676
10. Grez M., Zornig M., Nowock J., and Ziegler M. A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells. J. Virol. 65 (1991) 4691-4698
11. Beck-Engeser G., Stocking C., Just U., Albritton L., Dexter M., Spooncer E., and Ostertag W. Retroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and precursor cell lines, but retroviral infection is reduced in more primitive cells. Hum. Gene Ther. 2 (1991) 61-70
12. Eckert H.G., Stockschlader M., Just U., Hegewisch-Becker S., Grez M., Uhde A., Zander A., Ostertag W., and Baum C. High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood 88 (1996) 3407-3415
13. Kaneko S., Onodera M., Fujiki Y., Nagasawa T., and Nakauchi H. Simplified retroviral vector gcsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in nonobese diabetic/severe combined immunodeficient mice. Hum. Gene Ther. 12 (2001) 35-44
14. Engels B., Cam H., Schuler T., Indraccolo S., Gladow M., Baum C., Blankenstein T., and Uckert W. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. 14 (2003) 1155-1168
15. Ohnishi N., Itoh K., Itoh Y., Baum C., Higashitsuji H., Yamaguchi K., Tsuji T., Okanoue T., and Fujita J. High expression of transgenes mediated by hybrid retroviral vectors in hepatocytes: comparison of promoters from murine retroviruses in vitro and in vivo. Gene Ther. 9 (2002) 303-306
16. Hong Y., Yu S.S., Kim J.M., Lee K., Na Y.S., Whitley C.B., Sugimoto Y., and Kim S. Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome. J. Gene Med. 5 (2003) 18-29
17. + cells. J. Gene Med. 6 (2004) 724-733
18. Yu S.S., Han E., Hong Y., Lee J.T., and Kim S. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination. Gene Ther. 10 (2003) 706-711
19. Sanburn N., and Cornetta K. Rapid titer determination using quantitative real-time PCR. Gene Ther. 6 (1999) 1340-1345
20. Lizee G., Aerts J.L., Gonzales M.I., Chinnasamy N., Morgan R.A., and Topalian S.L. Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum. Gene Ther. 14 (2003) 497-507
21. Soneoka Y., Cannon P.M., Ramsdale E.E., Griffiths J.C., Romano G., Kingsman S.M., and Kingsman A.J. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23 (1995) 628-633
22. Wildner O., Candotti F., Krecko E.G., Xanthopoulos K.G., Ramsey W.J., and Blaese R.M. Generation of a conditionally neo(r)-containing retroviral producer cell line: effects of neo(r) on retroviral titer and transgene expression. Gene Ther. 5 (1998) 684-691
23. Byun J., Kim J.M., Robbins P.D., and Kim S. The selectable marker neo gene down-regulates gene expression from retroviral vectors containing an internal ribosome entry site. Gene Ther. 5 (1998) 1441-1444